Why Exelixis, Inc. Could Be a Gold Mine for Growth Investors
Exelixis (NASDAQ: EXEL) was one of the top biotech stocks of 2016. It's also one of the best biotech stocks so far this year. However, Exelixis shares have pulled back in recent days, primarily due to Bristol-Myers Squibb's (NYSE: BMY) announcement that it was halting a late-stage study of Opdivo and Yervoy in treating first-line renal cell carcinoma (RCC) earlier than expected because of positive results.
In my view, this latest pullback presents a solid buying opportunity. I think Exelixis stock could still be a gold mine for growth investors. Here's why.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Stock
€44.98
-0.870%
We see a rather positive sentiment for Bristol-Myers Squibb with 7 Buy predictions and 2 Sell predictions.
With a target price of 70 € there is a hugely positive potential of 55.64% for Bristol-Myers Squibb compared to the current price of 44.98 €.
